Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study.
Fabbri M, Leung C, Baille G, Béreau M, Brefel Courbon C, Castelnovo G, Carriere N, Damier P, Defebvre L, Doe de Maindreville A, Fluchere F, Fuzzatti M, Grabli D, Maltete D, Rousseau V, Sommet A A, Thalamas C, Thiriez C, Rascol O, Ory-Magne F. Fabbri M, et al. Among authors: rousseau v. Parkinsonism Relat Disord. 2021 Aug;89:128-133. doi: 10.1016/j.parkreldis.2021.07.013. Epub 2021 Jul 13. Parkinsonism Relat Disord. 2021. PMID: 34293534 Free PMC article.
Atropinic (Anticholinergic) Burden in Parkinson's Disease.
De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F. De Germay S, et al. Among authors: rousseau v. Mov Disord. 2016 May;31(5):632-6. doi: 10.1002/mds.26595. Epub 2016 Mar 29. Mov Disord. 2016. PMID: 27028036 Review.
Cognitive complaint in early Parkinson's disease: A pilot study.
Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group. Dupouy J, et al. Among authors: rousseau v. Acta Neurol Scand. 2018 Jan;137(1):59-66. doi: 10.1111/ane.12808. Epub 2017 Aug 22. Acta Neurol Scand. 2018. PMID: 28832893 Clinical Trial.
Abnormal pain perception in patients with Multiple System Atrophy.
Ory-Magne F, Pellaprat J, Harroch E, Galitzsky M, Rousseau V, Pavy-Le Traon A, Rascol O, Gerdelat A, Brefel-Courbon C. Ory-Magne F, et al. Among authors: rousseau v. Parkinsonism Relat Disord. 2018 Mar;48:28-33. doi: 10.1016/j.parkreldis.2017.12.001. Epub 2017 Dec 8. Parkinsonism Relat Disord. 2018. PMID: 29254664
Tamoxifen and the risk of Parkinsonism: a case/non-case study.
Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL. Montastruc F, et al. Among authors: rousseau v. Eur J Clin Pharmacol. 2018 Sep;74(9):1181-1184. doi: 10.1007/s00228-018-2496-3. Epub 2018 Jun 3. Eur J Clin Pharmacol. 2018. PMID: 29862427
Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson's Disease Patients (PSYCHO-STIM).
Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, Marques AR, Danaila T, Eusebio A, Devos D, Brefel-Courbon C; PREDI-STIM study group*. Boussac M, et al. Among authors: rousseau v. J Parkinsons Dis. 2020;10(3):1057-1066. doi: 10.3233/JPD-191903. J Parkinsons Dis. 2020. PMID: 32444557 Free article.
Personality dimensions of patients can change during the course of parkinson's disease.
Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland AS, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou N, Belamri L, Tir M, Marques AR, Thobois S, Eusebio A, Corvol JC, Devos D, Brefel-Courbon C; PREDI-STIM study group. Boussac M, et al. Among authors: rousseau v. PLoS One. 2021 Jan 7;16(1):e0245142. doi: 10.1371/journal.pone.0245142. eCollection 2021. PLoS One. 2021. PMID: 33411732 Free PMC article. Clinical Trial.
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
Rascol O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, Thalamas C, Sommet A, Rousseau V, Perez-Lloret S, Fabbri M, Azulay JP, Corvol JC, Couratier P, Damier P, Defebvre L, Durif F, Geny C, Houeto JL, Remy P, Tranchant C, Verin M, Tison F, Meissner WG; MSA-FLUO Study Group. Rascol O, et al. Among authors: rousseau v. Mov Disord. 2021 Jul;36(7):1704-1711. doi: 10.1002/mds.28569. Epub 2021 Apr 1. Mov Disord. 2021. PMID: 33792958 Free article. Clinical Trial.
Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II).
Boussac M, Arbus C, Klinger H, Eusebio A, Hainque E, Corvol JC, Rascol O, Rousseau V, Harroch E, d'Apollonia CS, Croiset A, Ory-Magne F, De Barros A, Fabbri M, Moreau C, Rolland AS, Benatru I, Anheim M, Marques AR, Maltête D, Drapier S, Jarraya B, Hubsch C, Guehl D, Meyer M, Rouaud T, Giordana B, Tir M, Devos D, Brefel-Courbon C; PREDISTIM study group. Boussac M, et al. Among authors: rousseau v. J Parkinsons Dis. 2022;12(2):699-711. doi: 10.3233/JPD-212883. J Parkinsons Dis. 2022. PMID: 34897100 Free article.
212 results